Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
Did you know?
How did MoneyWorks4me help subscribers to buy Divis Lab at Rs. 629/ share in 2017?
investing succesffuly to reach your goals investing succesffuly to reach your goals
X

Transgene Biotek Ltd Stock Analysis

Small Cap
Evaluated by 99 users | BSE: 526139 | NSE: |
Hospital & Healthcare Services

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20TTM
Return on Capital Employed 0.35%0.07%-0.55%-19.02%-9.33%-11.86%-17.21%-15.19%-24.66%-35.29%-
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 1026.31510.30.20.30.10.100
Y-o-Y Gr. Rt.-163.3%-42.7%-93.5%-68.4%-41.9%55.6%-57.1%-41.7%-100%-
Adjusted EPS (Rs.) 0.03-0.04-0.3-6.96-2.51-2.84-2.62-1.12-1.32-1.45-1.37
Y-o-Y Gr. Rt.--233.3%NANANANANANANANA-
Book Value per Share (Rs.) 52.8747.2848.9726.0223.5120.415.454.63.441.990.27
Adjusted Net Profit 0.1-0.2-2-52.8-19-21.5-19.9-8.5-10-11-10
Net Op. Cash Flow (Rs. Cr.) -1.125.399.6-2.1-100-0.6-1.70.1-
Debt to Cash Flow from Ops -18.640.820.23-6.2-15.15817.95692.85-15.75-5.2574.1-
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Transgene Biotek Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  10 yrs 5 yrs 3 yrs 1 yr
Net Sales -100%-100%-100%-100%
Adjusted EPS -253.9%NANANA
Book Value per Share -30.5-39-28.5-42.2
Share Price -21.6% 7.7% 1% -3.2%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20TTM
Return on Equity (%) 0.08-0.09-0.63-20.32-10.14-12.94-20.27-22.24-32.95-53.27-121.24
Operating Profit Margin (%) 11.934.5-5.56-185.35-480.9-623.14-910.9-1779.23-944.2-24147.06-97.36
Net Profit Margin (%) 1.37-0.93-13.23-5376.3-6047.65-11864.37-7071.71-7161.26-14076.04-306601.7-6,106.17
Debt to Equity 0.090.070.070.070.080.10.390.280.350.68-
Working Capital Days 1,8442,4884,09028,75287,3921,34,72954,93775,0861,21,12724,16,578-
Cash Conversion Cycle -19-8566,55519,84318,1021,1321551723,537-
Loading price chart...
Entity Percentage Holding
Promoters 23.64%
Non-Institutions 76.36%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Transgene Biotek Ltd's earnings have grown by 0%, whereas share price has appreciated 7.7% CAGR over the past five years, indicating the company’s share price is likely overvalued. However, for specific investment actions please consult your investment advisor.

Transgene Biotek Ltd share price has declined -21.6% annually (CAGR) over the past ten years.

Data is not available for this company.

Transgene Biotek Ltd (TBL) was set up in 1991, and was probably the first true Biotechnology Company in India. It is listed on the Indian Stock Exchanges and is involved in the development of several cutting edge technologies.

From the knowledge gained in developing recombinant vaccines successfully since 1994, and having gained considerable experience in improving the technology processes of those products, Transgene has expanded its product portfolio to other therapeutic areas such as

Transgene Biotek Ltd (TBL) was set up in 1991, and was probably the first true Biotechnology Company in India. It is listed on the Indian Stock Exchanges and is involved in the development of several cutting edge technologies.

From the knowledge gained in developing recombinant vaccines successfully since 1994, and having gained considerable experience in improving the technology processes of those products, Transgene has expanded its product portfolio to other therapeutic areas such as Bio-generics, Oncology and New Drug Delivery Systems among others.

In line with its expanded product development portfolio, Transgene is modifying its existing infrastructure to cater to further Research & Development activities and is presently constructing a new manufacturing facility to meet WHO and US FDA standards.  Transgene is focused on maximizing synergies through strategic partnerships. We are excited to explore opportunities with partners and catalyze technological advances in the field of biotechnology.   Since 1994, Transgene Biotek has developed or has been involved in the development of technology for several different bio-pharmaceuticals, recombinant vaccines and therapeutics. We have extensive experience and expertise to assist you in recombinant drug development, characterization, testing and validation.

Product range of the company includes:

The company is engaged in manufacturing drugs for:

New Drug Delivery System (NDDS)

  • Oral Delivery of Insulin
  • Oral Delivery Hepatitis B Vaccine
  • Pegylation of Protein Drugs for Sustained Release

Biogeneries

  • Tacrolimus 
  • Pegylated EPO 

Human Vaccines

  • Meningococcal Meningitis
  • Universal Meningococcal Meningitis
  • Haemophilus Influenza B-Hib
  • DTP+Hib+Hep B Combination
  •  Hepatitis A+B Combination 

Cancer Drugs/Oncology

  • Multiple Myeloma
  • Barrett's Esophageal Cancer
  • Colon Cancer
  • Breast Cancer  

  

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback